Interferon Kappa Is Up-Regulated in Psoriasis and It Up-Regulates Psoriasis-Associated Cytokines in vivo

References

• Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983–994. doi:10.1016/S0140-6736(14)61909-726025581
   PubMed Web of Science ®Google Scholar
• Kaufman BP, Alexis AF. Psoriasis in skin of color: insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in non-white racial/ethnic groups. Am J Clin Dermatol. 2018;19(3):405–423. doi:10.1007/s40257-017-0332-729209945
   PubMed Web of Science ®Google Scholar
• Lebwohl M. Psoriasis. Lancet. 2003;361(9364):1197–1204. doi:10.1016/S0140-6736(03)12954-612686053
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. doi:10.1038/jid.2012.33923014338
   PubMed Web of Science ®Google Scholar
• Yao Y, Richman L, Morehouse C, et al. Type I interferon: potential therapeutic target for psoriasis? PLoS One. 2008;3(7):e2737. doi:10.1371/journal.pone.000273718648529
   PubMed Web of Science ®Google Scholar
• Georgescu SR, Tampa M, Caruntu C, et al. Advances in understanding the immunological pathways in psoriasis. Int J Mol Sci. 2019;20:3. doi:10.3390/ijms20030739
   Web of Science ®Google Scholar
• Dong J, Goldenberg G. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors. Cutis. 2017;99(2):123–127.28319618
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014–2022. doi:10.1056/NEJMoa03040914627786
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi:10.1016/j.jaad.2018.11.05730772098
   PubMed Web of Science ®Google Scholar
• Baldwin HM, Pallas K, King V, et al. Microarray analyses demonstrate the involvement of type I interferons in psoriasiform pathology development in D6-deficient mice. J Biol Chem. 2013;288(51):36473–36483. doi:10.1074/jbc.M113.49156324194523
   PubMed Web of Science ®Google Scholar
• Schmid P, Itin P, Cox D, McMaster GK, Horisberger MA. The type I interferon system is locally activated in psoriatic lesions. J Interferon Res. 1994;14(5):229–234. doi:10.1089/jir.1994.14.2297861026
   PubMedGoogle Scholar
• van der Fits L, van der Wel LI, Laman JD, Prens EP, Verschuren MC. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol. 2004;122(1):51–60. doi:10.1046/j.0022-202X.2003.22113.x14962089
   PubMed Web of Science ®Google Scholar
• LaFleur DW, Nardelli B, Tsareva T, et al. Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem. 2001;276(43):39765–39771. doi:10.1074/jbc.M10250220011514542
   PubMed Web of Science ®Google Scholar
• Nardelli B, Zaritskaya L, Semenuk M, et al. Regulatory effect of IFN-kappa, a novel type I IFN, on cytokine production by cells of the innate immune system. J Immunol. 2002;169(9):4822–4830. doi:10.4049/jimmunol.169.9.482212391192
   PubMed Web of Science ®Google Scholar
• Harley IT, Niewold TB, Stormont RM, et al. The role of genetic variation near interferon-kappa in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010.
   Google Scholar
• Sarkar MK, Hile GA, Tsoi LC, et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis. 2018;77(11):1653–1664. doi:10.1136/annrheumdis-2018-21319730021804
   PubMed Web of Science ®Google Scholar
• Stannard JN, Reed TJ, Myers E, et al. Lupus skin is primed for IL-6 inflammatory responses through a keratinocyte-mediated autocrine type I interferon loop. J Invest Dermatol. 2017;137(1):115–122. doi:10.1016/j.jid.2016.09.00827646883
   PubMed Web of Science ®Google Scholar
• Scarponi C, Nardelli B, Lafleur DW, et al. Analysis of IFN-kappa expression in pathologic skin conditions: downregulation in psoriasis and atopic dermatitis. J Interferon Cytokine Res. 2006;26(3):133–140. doi:10.1089/jir.2006.26.13316542135
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1–11. doi:10.1016/j.jaci.2018.10.03230612663
   PubMed Web of Science ®Google Scholar
• Reiser J, Hurst J, Voges M, et al. High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol. 2011;85(21):11372–11380. doi:10.1128/JVI.05279-1121849431
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732–738. doi:10.1038/3509956011607032
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol. 2008;20(1):17–22. doi:10.1016/j.coi.2008.01.00218272355
   PubMed Web of Science ®Google Scholar
• Zhong B, Zhang L, Lei C, et al. The ubiquitin ligase RNF5 regulates antiviral responses by mediating degradation of the adaptor protein MITA. Immunity. 2009;30(3):397–407. doi:10.1016/j.immuni.2009.01.00819285439
   PubMed Web of Science ®Google Scholar
• Saha B, Kodys K, Adejumo A, Szabo G. Circulating and exosome-packaged hepatitis C single-stranded RNA induce monocyte differentiation via TLR7/8 to polarized macrophages and fibrocytes. J Immunol. 2017;198(5):1974–1984. doi:10.4049/jimmunol.160079728122964
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653. doi:10.1016/j.jaci.2017.07.00428887948
   PubMed Web of Science ®Google Scholar
• Keermann M, Koks S, Reimann E, Prans E, Abram K, Kingo K. Transcriptional landscape of psoriasis identifies the involvement of IL36 and IL36RN. BMC Genomics. 2015;16:322. doi:10.1186/s12864-015-1508-225897967
   PubMed Web of Science ®Google Scholar
• Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol. 2005;6(4):328–340. doi:10.1038/nrm161915803139
   PubMed Web of Science ®Google Scholar
• McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87–103. doi:10.1038/nri378725614319
   PubMed Web of Science ®Google Scholar
• Schreiber G. The molecular basis for differential type I interferon signaling. J Biol Chem. 2017;292(18):7285–7294. doi:10.1074/jbc.R116.77456228289098
   PubMed Web of Science ®Google Scholar
• Ruano J, Suarez-Farinas M, Shemer A, Oliva M, Guttman-Yassky E, Krueger JG. Molecular and cellular profiling of scalp psoriasis reveals differences and similarities compared to skin psoriasis. PLoS One. 2016;11(2):e0148450. doi:10.1371/journal.pone.014845026849645
   PubMed Web of Science ®Google Scholar
• Afshar M, Martinez AD, Gallo RL, Hata TR. Induction and exacerbation of psoriasis with interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad Dermatol Venereol. 2013;27(6):771–778. doi:10.1111/jdv.2013.27.issue-622671985
   PubMed Web of Science ®Google Scholar
• Tas F, Atsu N. Exacerbation of psoriasis induced by interferon-alpha treatment for melanoma. Cutan Ocul Toxicol. 2016;35(1):83–84. doi:10.3109/15569527.2015.102054525799214
   PubMed Web of Science ®Google Scholar
• Wu MC, Lee JY. Generalized flare of pustular psoriasis induced by PEGylated interferon-alpha2b therapy for chronic hepatitis C. Australas J Dermatol. 2012;53(4):e69–72. doi:10.1111/j.1440-0960.2011.00767.x23157789
   PubMed Web of Science ®Google Scholar
• Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005;202(1):135–143. doi:10.1084/jem.2005050015998792
   PubMed Web of Science ®Google Scholar
• Livden JK, Nilsen R, Bjerke JR, Matre R. In situ localization of interferons in psoriatic lesions. Arch Dermatol Res. 1989;281(6):392–397. doi:10.1007/BF004553232480752
   PubMed Web of Science ®Google Scholar
• Zhang LJ, Sen GL, Ward NL, et al. Antimicrobial peptide LL37 and MAVS signaling drive interferon-beta production by epidermal keratinocytes during skin injury. Immunity. 2016;45(1):119–130. doi:10.1016/j.immuni.2016.06.02127438769
   PubMed Web of Science ®Google Scholar
• Furiati SC, Catarino JS, Silva MV, et al. Th1, Th17, and treg responses are differently modulated by TNF-alpha inhibitors and methotrexate in psoriasis patients. Sci Rep. 2019;9(1):7526. doi:10.1038/s41598-019-43899-931101850
   PubMed Web of Science ®Google Scholar
• Keijsers RR, Joosten I, van Erp PE, Koenen HJ, van de Kerkhof PC. Cellular sources of IL-17 in psoriasis: a paradigm shift? Exp Dermatol. 2014;23(11):799–803. doi:10.1111/exd.1248725039885
   PubMed Web of Science ®Google Scholar